Surgery Clinical Trial
Official title:
The Effect of Universal Pre-hospital Naloxone Education on Patient and Family Safety, Attitudes and Experience in the Surgical Patient: a Prospective Randomized Trial
This study examines the efficacy of a brief pre-hospital naloxone education module added to the standard "Total Joint Class" curriculum on patient safety and experience. Participants will consist of 250 patient-and-support-person pairs. The primary outcome is "readiness to use" naloxone - a proxy for opioid overdose safety. Patient factors contributing to this primary outcome as well as the effect on patient attitude and experience will also be investigated.
Status | Not yet recruiting |
Enrollment | 500 |
Est. completion date | December 2022 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients and "primary support person" pairs in which - the patient is planning total or partial elective hip replacement at Carilion Roanoke Memorial Hospital OR - the patient is planning total or partial elective knee replacement at Carilion Roanoke Memorial Hospital OR - willingness to participate in study activities Exclusion Criteria: - Age < 18 years - Pregnancy - Poor cognitive function - Poor English language skills - Inmate |
Country | Name | City | State |
---|---|---|---|
United States | Institute for Orthopedics and Neurosciences | Roanoke | Virginia |
Lead Sponsor | Collaborator |
---|---|
Carilion Clinic | Virginia Polytechnic Institute and State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | "Readiness to Use Naloxone" assessed by survey and Opioid Overdose Knowledge Scale administration | This measure is expressed as a binary yes/no for each patient-support person pair. It can be assessed with the survey tool used at the patient's follow up appointment. The patient/ support person pair must satisfy each of the three following conditions.
patient reports naloxone is present in the home (or carried with the patient) (assessed by Y/N question) the support person reports knowledge of and immediate access to the naloxone (assessed by Y/N question) the support person demonstrates competency for naloxone administration by scoring a passing mark on the modified Opioid Overdose Knowledge Scale (OOKS) (Williams et al. 2013). For our purposes, this will be a score greater than or equal to 34/45. If the three conditions are met, then the pair is assessed a "yes" score on "Readiness to Use Naloxone". If any condition is not met, then the pair is assessed a "no" score on "Readiness to Use Naloxone". |
approximately 2 weeks (from surgery to first follow-up visit) | |
Secondary | Correlation between indication for surgery (described by International Classification of Diseases 9/10 code) and "Readiness to Use Naloxone" | "Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
Indications for surgery are described by International Classification of Diseases 9/10, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include: Musculoskeletal 16-Osteoarthritis of the Hip Musculoskeletal 17-Osteoarthritis of the Knee |
2 months (time from study enrollment to first post-op visit) | |
Secondary | Correlation between procedure (Current Procedural Terminology code) and "Readiness to Use Naloxone" | "Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
The operations that patients undergo are described by Current Procedural Terminology codes, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include: 1005073- Arthroplasty, knee, condyle and plateau 27130 - Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft |
2 months (time from study enrollment to first post-op visit) | |
Secondary | Correlation between patient comorbidities (described by International Classification of Diseases 9/10 code and "Readiness to Use Naloxone" | "Readiness to Use Naloxone" as described in our primary outcome measure will be used in the majority of our secondary outcomes. It functions as a binary variable.
Comorbidities are other elements of a patient's health that are identified by their primary care physicians or other specialists. These comorbidities International Classification of Diseases 9/10, which are categorical variables with a uniform unit of measure. These codes are entered into the patient's electronic medical record by the patient's surgeon and would be retrieved by a study team member. Codes expected to be present in the study include: Musculoskeletal 16-Osteoarthritis of the Hip Musculoskeletal 17-Osteoarthritis of the Knee |
2 months (time from study enrollment to first post-op visit) | |
Secondary | correlation between patient age and "Readiness to Use Naloxone" | age (exploratory analysis) | 2 months (time from study enrollment to first post-op visit) | |
Secondary | correlation between patient sex and "Readiness to Use Naloxone" | sex (exploratory analysis) | 2 months (time from study enrollment to first post-op visit) | |
Secondary | correlation between patient race and "Readiness to Use Naloxone" | race (exploratory analysis) | 2 months (time from study enrollment to first post-op visit) | |
Secondary | correlation between patient ethnicity and "Readiness to Use Naloxone" | ethnicity (exploratory analysis) | 2 months (time from study enrollment to first post-op visit) | |
Secondary | correlation between patient household income and "Readiness to Use Naloxone" | household income (exploratory analysis) | 2 months (time from study enrollment to first post-op visit) | |
Secondary | Amount of opioid used at home | milligrams of morphine equivalents | 7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Interference 6a assessments | Each question usually has five response options ranging in value from one to five. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For the adult 6-item form, the lowest possible raw score is 6; the highest possible raw score is 30 (see all short form scoring tables in Appendix 1). All questions must be answered in order to produce a valid score using the scoring tables. If a participant has skipped a question, use the HealthMeasures Scoring Service (https://www.assessmentcenter.net/ac_scoringservice) to generate a final score. Locate the applicable score conversion table in Appendix 1 and use this table to translate the total raw score into a T-score for each participant. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. | 7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | Post-operative pain as measured by the Patient Reported Outcome Measurement Information System Pain Intensity 3a | Each question has five response options ranging in value from one to five. To find the total raw score for the short form, sum the values of the response to each question. The lowest possible raw score is 3; the highest possible raw score is 15.
For most Patient-Reported Outcomes Measurement Information System instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. The T-score is provided with an error term (Standard Error or SE). The Standard Error is a statistical measure of variance and represents the "margin of error" for the T-score. Important: A higher Patient-Reported Outcomes Measurement Information System T-score represents more of the concept being measured. |
7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | High risk behavior as measured by the Patient Reported Outcome Measurement Information System Pain Medication Misuse assessment | Each question has five response options ranging in value from one to five. To find the total raw score for the short form, sum the values of the response to each question. For this instrument, the lowest possible raw score is 7; the highest possible raw score is 35. All questions must be answered in order to produce a valid score.
For most Patient-Reported Outcomes Measurement Information System instruments, a score of 50 is the average for the United States general population with a standard deviation of 10 because calibration testing was performed on a large sample of the general population. The T-score is provided with an error term (Standard Error or SE). The Standard Error is a statistical measure of variance and represents the "margin of error" for the T-score. |
7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | Patient and caregiver knowledge | Opioid Overdose Knowledge Scale: The Opioid Overdose Knowledge Scale items use a 'yes/no or don't know'; or 'true/false or don't know' response format.
Each correct answer scores one point. 'Don't know' and incorrectly marked responses (mistakes) are scored zero. Total score range: 0-45 points. OPIOID OVERDOSE KNOWLEDGE SCALE (OOKS): INSTRUCTIONS Total Score (45 items): One point if marked (33 Correct/True items): 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, 1i, 2b, 2c, 2d, 2e, 2g, 2h, 3a, 3b, 3d, 3f, 3g, 3i, 3j, 4a, 5a, 5b, 5c, 6a, 7a, 8b, 9T, 11T, 12T, 14T One point if NOT marked (12 Incorrect/False items): 2a, 2f, 2i, 2j, 3c, 3e, 3h, 3k, 5d, 5e, 10F, 13F. You might chose to use the 'record into same variables' function of Statistical Package for the Social Sciences and inverse the values of these items. |
7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | Patient and caregiver attitude | Opioid Overdose Attitude Scale: SCORING The Opioid Overdose Attitude Scale is scored continuously using a 5-point Likert scale: completely disagree (1 point), disagree (2 points), unsure (3 points), agree (4 points) and completely agree (5 points).
Reverse negative items: The following negative items need to be reversed before computing the total of scale points: 4, 6, 7, 9, 11, 15, 16, 17, 18, 23, 24, 25. You can use the 'record into same variables' OPIOID OVERDOSE ATTITUDES SCALE (OOAS): INSTRUCTIONS function of Statistical Package for the Social Sciences. Recode these items as: completely disagree (5 point), disagree (4 points), unsure (3 points), agree (2 points) and completely agree (1 points). Totals Scores: Once negative items have been reversed, add all items' points. The total scale points can range from 28 to 140 points. |
7 months (time from enrollment to 6 month follow-up phone call) | |
Secondary | Prescription fill rate | patient reports naloxone is present in the home (or carried with the patient) | approximately 2 weeks (from surgery to first follow-up visit) | |
Secondary | Naloxone accessibility | "yes/no" answer to the question: "Do you know where naloxone is stored in the home and have immediate access to it in an emergency?" | approximately 2 weeks (from surgery to first follow-up visit) | |
Secondary | Rescuer competence measured by modified Opioid Overdose Knowledge Scale Score (see outcome 14 for scoring) | the support person demonstrates competency for naloxone administration by scoring a passing mark (34/45) on the modified Opioid Overdose Knowledge Scale | approximately 2 weeks (from surgery to first follow-up visit) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Enrolling by invitation |
NCT05534490 -
Surgery and Functionality in Older Adults
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Terminated |
NCT04612491 -
Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
|
||
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04204785 -
Noise in the OR at Induction: Patient and Anesthesiologists Perceptions
|
N/A | |
Completed |
NCT03432429 -
Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
|
||
Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Recruiting |
NCT04602429 -
Children's Acute Surgical Abdomen Programme
|
||
Completed |
NCT03124901 -
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor
|
N/A | |
Completed |
NCT04595695 -
The Effect of Clear Masks in Improving Patient Relationships
|
N/A | |
Recruiting |
NCT06103136 -
Maestro 1.0 Post-Market Registry
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Completed |
NCT04059328 -
Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
|
||
Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |